About this trial
This trial collects research data and samples from patients who experience immunotherapy side effects to store for use in future research studies. Studying research data and samples from patients who experience immunotherapy side effects may help researchers better understand how to predict, prevent, and treat these side effects.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Received a regimen containing one or more immuno-oncology therapeutics
One or more serious (Grade 3-4) AEs that are likely immune-related
One or more Grade 2 dermatologic or rheumatologic AEs that are likely immune-related
Diagnosis of a rare infection, e.g., fungal or mycobacterial, after starting IO treatment
Disqualifiers
None
Trial population
Patients who have received one or more immuno-oncology therapeutics and experienced one or more serious adverse events (AEs)
Trial design
Cohort
Prospective
Treatments tested in this trial
Biospecimen Collection
Procedure/SurgeryUndergo collection of tissue, blood, and stool samples
Medical Chart Review
Other interventionReview of medical records
Treatment groups
Trial outcomes
Primary outcomes
Establishment of a national biorepository including biospecimen and clinical data collections for future use
The objective of this study to establish a biorepository of biospecimen and clinical data. There is no primary clinical outcome for this study.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Alliance for Clinical Trials in Oncology
Lead sponsor
National Cancer Institute (NCI)
Collaborator